---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-258565"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:30:06.728645+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veru prices $25.2M public offering of common stock and warrants; net proceeds ~$23.4M for enobosarm study

## Summary
- Offering includes 1.4M common shares + 7M pre-funded warrants and 8.4M Series A and 8.4M Series B warrants at $3.00/unit.
- Gross proceeds expected ~$25.2M; net proceeds ~$23.4M after underwriting discounts and expenses.
- Closing expected on or about October 31, 2025, subject to customary conditions.
- Proceeds primarily to fund Phase 2b PLATEAU clinical study of enobosarm; also for working capital and general corporate purposes.
- Series A warrants expire 5 years from issuance; Series B warrants expire 3 years or upon meeting specific clinical milestones and stock price triggers.

## SEC filing metadata
- accession: 0001193125-25-258565
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312525258565/0001193125-25-258565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312525258565/d59421d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-258565
- JSON: https://secwatch.observer/filing/0001193125-25-258565.json
- Plain text: https://secwatch.observer/filing/0001193125-25-258565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.